|
|||||
|
|
|
|
|
|
Select publications
Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Abstract
Escudier B et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 2006;Abstract 4501.
Genentech BioOncology. Interim analysis of phase III trial shows Avastin plus interferon therapy improved progression-free survival in patients with previously untreated advanced renal cell carcinoma. Available at http://www.gene.com/gene/news/press-releases/index.jsp
Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med 2007;356(2):115-24. Abstract
Motzer RJ et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 2006; Abstract LBA3
Rini BI et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99(1):81-3. Abstract
Rini BI et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10(8):2584-6. Abstract
Ryan CW et al. Sorafenib plus interferon-alpha2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. Proc ASCO 2006;Abstract 4525.
Tamaskar I et al. Antitumor effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Proc ASCO 2006;Abstract 4597.
Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract
 |
Terms of Use and General Disclaimer. | Privacy Policy Copyright © 2007 Research To Practice. All Rights Reserved. |
 |
